Drug Eruptions Treatment Market

Drug Eruptions Treatment Market Snapshot (2023 to 2033)

The global drug eruptions treatment market is expected to be worth USD 3.89 Billion in the fiscal year 2023, which rose up from USD 3.66 Billion in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 6.2% CAGR, reaching a value of USD 7.1 Billion by the end of 2033.

A drug eruption is an unpleasant cutaneous response to a medication. Many medicines, including antimicrobials, NSAIDs, anticonvulsants, sulfa drugs, chemotherapeutic agents, and psychiatric meds, can induce adverse effects. Drug eruption treatment can mimic a range of different skin disorders and should therefore be evaluated in any patient who is taking drugs or has switched medications. Drug eruptions treatment often appears after 2 weeks of starting a new drug or even within days if re-exposure to a specific drug. Scratching is the most prevalent symptom.

Drug eruption treatment occurs in about 2-5% of hospitalized patients and more than 1% of outpatients. Adverse medication responses are more common in women, the elderly, and individuals with impaired immune systems.

The best way to cure a drug rash is to discontinue the medicine that is triggering it. After quitting a medication, it may require 5-10 days for the skin to heal and up to 3 weeks for the rashes to entirely resolve. Oral antihistamine tablets such as hydroxyzine, diphenhydramine, loratadine, fexofenadine, cetirizine, or desloratadine for irritation; topical corticosteroids (cortisone) lotions or creams for red, inflamed skin; and topical antimicrobial ointments for open sores are other options.

Attributes	Details
Expected Market Value (2023)	USD 3.89 Billion
Projected Forecast Value (2033)	USD 7.1 Billion
Global Growth Rate (2023 to 2033)	6.2%

2018 To 2022 Drug eruptions treatment Market Demand Analysis Vs. Forecast 2023 To 2033

The global drug eruption treatment market grew at a CAGR of 5.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. In most cases, drug eruptions treatment is identified clinically. Skin tests, for example, are performed in laboratories due to their great specificity. Treatment is often beneficial and includes discontinuation of the incorrect drug, indicated treatment, and patient education. For example, people who are allergic to penicillin are recommended to avoid all carbapenems as well as cephalosporins for their own safety. Such factors have been a major driver of this market for drug eruptions treatment.

The global drug eruptions treatment market is being driven by the introduction of innovative treatment approaches, increased knowledge of different drug allergies, and a growth in demand in emerging economies. The development of new medications and intensive continuing research for the prevention of any sort of drug allergy are important to market drivers. The global market for drug eruption treatment is expanding at a modest rate, which is projected to continue over the forecast period.

Such factors are expected to boost the global sales of drug eruptions treatment solutions. As a result, the global drug eruptions treatment market is expected to forecast a CAGR of over 6% from 2023 to 2033.

Prominent Growth Drivers Influencing drug eruptions treatment market

Various kinds of allergies to different drug types boost the demand

Both over-the-counter and prescription medications have the potential to be the problem. Antibiotics as well as other antimicrobial medications, sulfa medications, nonsteroidal anti-inflammatory medicines (NSAIDs), chemotherapeutic agents, anticonvulsants, biopharmaceuticals, and psychiatric medications are a few examples of common medications that can result in drug eruptions treatment. Examples of common reactions include photodermatitis brought on by topical NSAIDs (like piroxicam) or antibiotics (like minocycline), fixed drug eruptions treatment brought on by acetaminophen or NSAIDs (like Ibuprofen), and the rash that develops after ampicillin in instances of mononucleosis.

The rate of drug eruption treatment associated with several medications is thought to be fewer than 3 per 100 people exposed. Digoxin, aluminum hydroxide, vitamin supplements, bisacodyl, acetaminophen, aspirin, prednisone, thiamine, atropine, hydrochlorothiazide, codeine, morphine, warfarin, insulin, and spironolactone are a few of these. Such factors are sure to propel the market for drug eruptions treatment during the forecast period.

Several treatments for drug eruptions treatment to accelerate the growth

Drug eruptions treatment is being treated with a variety of medications. Desensitization, for instance, is occasionally used to treat drug eruptions treatment, especially when testing is not possible or available. As long as one keeps taking the medication, this method aims to temporarily enable the body to tolerate allergens.

For instance, during penicillin desensitization, progressively greater doses of penicillin are given at intervals until the immune system becomes used to the medication. Such developments are expected to accelerate the demand for drug eruption treatment during the forecast period.

What Could Possibly Hinder Drug eruptions treatment Market Demand? 

High costs and increasing pharmacovigilance impede the global market

During the review period, one of the biggest obstacles facing the worldwide market for drug eruptions treatment may be the high cost linked with them. Additionally, the advancement in drug eruptions treatment calls for highly qualified personnel, which might be one of the biggest obstacles for the global market.

Increasing pharmacovigilance at the same time can help to lessen drug side effects and, as a result, stop any potential eruptions caused by various medications. Thus, such factors can impede the growth of this market and hence curtail the demand for the treatment of drug eruptions treatment.

Region-wise Analysis

What is the outlook of the North American drug eruptions treatment market?

Rising technological advancements and skin rashes boost the regional demand

North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for drug eruption treatment, with a dominant 7.3% CAGR from 2023 to 2033.

This fast CAGR can be attributed to the increasing number of skin allergy sufferers in the United States of America, improved healthcare facilities, increased research and development in this domain, and cutting-edge technologies. Black Americans suffer mostly from various skin rashes and eruptions due to the various drugs, which lead to eczema and skin inflammation along with hay fever.

In the United States of America, a survey from 2021 found that among people who reported drug eruptions treatment, penicillin and related medicines accounted for 18% of cases. In addition, one in ten persons had an allergy to sulfonamide-containing antibiotics. Hence, there would be a lot of scopes for North American manufacturers to develop in this market during the forecast period.

What can be expected from the European market for drug eruptions treatment?

Increasing treatment options and innovations to propel the sales

During the forecast period, the European market for drug eruptions treatment is expected to garner a steady CAGR of 6.2%. But at the time, the European market for the management of drug eruptions treatment is expected to witness this market gain 27% in 2023.

Drug allergies affect 1% to 2% of hospital admissions and 3% to 5% of outpatients in the United Kingdom, however, it is unknown how common they are in the general population, including children and adults. Hence, the increasing incidence of drug reaction cases has made the European market an attraction for global manufacturers. The presence of the key players in this market has accelerated the revenues for the European market for drug eruptions treatment. Such developments are expected to accelerate the growth in the market from 2023 to 2033.

Category-wise Insights

Which drug type segment is expected to gain traction from 2023 to 2033?

The antihistamines segment will gain the dominant market share

Over the course of the forecast period, the antihistamine segment by product type is anticipated to occupy a significant share of the global drug eruptions treatment market. In 2023, this category is anticipated to dominate with a 41% revenue share.

Antihistamines may cause unforeseen type B adverse drug events, irrespective of the mechanism, thus it's critical to pay attention to the patient's condition in order to spot such bad reactions. Antihistamines are crucial medications used to treat urticaria and anaphylaxis, but it's vital to remember that antihistamines do have certain risks associated with their usage.

Also, antihistamines can cause bigger lesions on the epidermis, which can further lead to serious conditions. Such factors are expected to accelerate the growth prospects for drug eruptions treatment from 2023 to 2033.

Which route of administration segment is expected to gain traction from 2023 to 2033?

The intravenous segment will demand during the forecast period.

According to the research by Future Market Insights, the intravenous segments will gain popularity during the forecast period. It is anticipated that this segment will occupy a global market share of 25% from 2023 to 2033.

During a case of drug eruptions treatment, most of the time, the symptoms cannot be barred by the oral drugs solely. In such a case, the drug needs to be injected directly into the bloodstream so that they start working quickly. With the IV route of administration, the patients get faster relief from the various allergic reactions within their bodies. These benefits are expected to people the growth of this segment from 2023 to 2033.

Start-up Scenario

The new companies in this market are aimed at developing novel solutions for various kinds of drug eruptions treatment and allergies by curing the symptoms first. Some of the companies are:

• Bioherent was created in 2021 to further the development of its laboratory prototype, which employs ultra-sensitive photonic biosensors to identify medication allergies, including beta-lactam antibiotics. One significant advantage of their approach was that, unlike previous integrated photonic biosensor devices, it did not need demanding components, making it relatively inexpensive to make and simple to deploy.
• Using data and clinical research, Nectar creates a complete, vertically integrated allergy healthcare platform. The Nectar platform will employ data and clinical studies to provide individualized allergy care that will treat the underlying cause of allergies and provide long-term relief. Nectar's distinct strategy will give long-needed ease to clients by effortlessly transitioning between virtual treatment and physical clinics for complete allergy care addressing environmental, pet, eczema, drug allergies, and asthma.

Competitive Landscape 

Some of the prominent players in the global market for drug eruptions treatment are:

• Anuh Pharma Ltd.
• Avik Pharma
• Pfizer CentreOne
• Hovione
• Bausch Health Companies Inc.
• APOTEX
• Astellas Pharma, Inc.
• Sanofi
• Novartis AG
• SBH Sciences

Some of the prominent developments of the key players in the market are:

• Novartis announced in 2021 that the FDA has given ligelizumab (QGE031) the designation of 'Breakthrough Therapy' for the treatment of chronic spontaneous urticaria (CSU), commonly known as chronic idiopathic urticaria (CIU), in individuals who had an unsatisfactory reaction to H1-antihistamine therapy. Ligelizumab (QGE031) is a monoclonal anti-immunoglobulin E (IgE) antibody of the next generation. Ligelizumab is considered to act by inhibiting the IgE/FcRI pathway, which is known to be the main driver of the inflammation reaction in CSU. Ligelizumab against omalizumab is now being studied in Phase III clinical trial programs such as PEARL 1 and PEARL 2. (NCT03580369 and NCT03580356). The clinical studies have enrolled over 2,000 patients from 48 countries worldwide.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 6.2% from 2023 to 2033
Market value in 2023	USD 3.89 Billion
Market value in 2033	USD 7.1 Billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	USD Billion for Value
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Drug class, Route of Administration, Distribution Channel, Region
Regions Covered	North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA)
Key Countries Profiled	United States of America, Canada, Mexico, Brazil, Rest of Latin America, Germany, Italy, France, United Kingdom, Spain, Rest of Europe, Japan, Singapore, South Korea, Thailand, Indonesia, China, Australia, New Zealand, Japan, GCC Countries, South Africa, Israel, Middle East and Africa
Key Companies Profiled	Anuh Pharma Ltd.; Avik Pharma; Pfizer CentreOne; Hovione; Bausch Health Companies Inc.; APOTEX; Astellas Pharma, Inc.; Sanofi; Novartis AG; SBH Sciences
Customisation Scope	Available on Request

Frequently Asked Questions

What is the Growth Potential of the Market?

The market is forecast to register a CAGR of 6.2% through 2033.

What is the Projected Size of the Market by 2033?

The market is valued to reach USD 7.1 Billion by 2033.

What Historical Changes Did the Market Undergo?

The global market advanced at a 5.1% HCAGR from 2018 to 2022.

Which Section May Become Vital Based on Drug Type?

The antihistamines sector is anticipated to grasp a sizable market share of 41%.

What Route of Administration Segment Will Capture a Large Share of the Market?

A sizeable 25% share pertains to the intravenous category.

What is the CAGR of the Europe Market?

The European market to garner a steady CAGR of 6.2%.